MetLife
MET · Life & Health Insurance
$98.82
4.6%Prudential Financial
PRU · Life & Health Insurance
$114.99
2.7%The short version
- MetLife is the larger business, with $77.1B of revenue in fiscal 2025 against $60.8B for Prudential Financial.
- MetLife grew revenue faster (8.6%, against −13.7%).
- Investors pay more for each dollar of MetLife’s earnings: a P/E of 18.9x against 10.4x for Prudential Financial.
| Latest fiscal year | MET · FY25 | PRU · FY25 |
|---|---|---|
| Size | ||
| Market cap | $63.9B | $40.0B |
| Revenue | $77.1B | $60.8B |
| Free cash flow | — | — |
| Net income | $3.4B | $3.6B |
| Growth | ||
| Revenue growth | 8.6% | −13.7% |
| 5-year growth | 2.6% | 1.3% |
| Share count change | −5.3% | −1.6% |
| Profitability | ||
| Gross margin | — | — |
| Operating margin | 8.0% | — |
| Net margin | 4.4% | 5.9% |
| FCF margin | — | — |
| Return on capital | — | — |
| Return on equity | — | — |
| Balance sheet | ||
| Net debt | −$10.8B | −$856M |
| Net debt / EBITDA | −1.7x | −0.1x |
| Dividends and buybacks | $4.4B | $2.9B |
| Valuation & quality | ||
| P/E | 18.9x | 10.4x |
| Piotroski F-score | — | — |
FY16
MET $60.8B
PRU $58.8B
FY17
MET $62.3B
PRU $59.7B
FY18
MET $67.9B
PRU $63.0B
FY19
MET $69.6B
PRU $64.8B
FY20
MET $67.8B
PRU $57.0B
FY21
MET $68.7B
PRU $71.2B
FY22
MET $68.8B
PRU $56.9B
FY23
MET $66.9B
PRU $54.0B
FY24
MET $71.0B
PRU $70.4B
FY25
MET $77.1B
PRU $60.8B
MET
PRU
FY16
MET —
PRU —
FY17
MET —
PRU —
FY18
MET —
PRU —
FY19
MET —
PRU —
FY20
MET —
PRU —
FY21
MET —
PRU —
FY22
MET 8.7%
PRU —
FY23
MET 8.6%
PRU —
FY24
MET 8.5%
PRU —
FY25
MET 8.0%
PRU —
MET
PRU
FY16
MET —
PRU —
FY17
MET —
PRU —
FY18
MET —
PRU —
FY19
MET —
PRU —
FY20
MET —
PRU —
FY21
MET —
PRU —
FY22
MET —
PRU —
FY23
MET —
PRU —
FY24
MET —
PRU —
FY25
MET —
PRU —
MET
PRU
FY16
MET —
PRU —
FY17
MET —
PRU —
FY18
MET —
PRU —
FY19
MET —
PRU —
FY20
MET —
PRU —
FY21
MET —
PRU —
FY22
MET —
PRU —
FY23
MET —
PRU —
FY24
MET —
PRU —
FY25
MET —
PRU —
MET
PRU
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.